Recent Research Analysts’ Ratings Changes for Syros Pharmaceuticals (SYRS)

Several analysts have recently updated their ratings and price targets for Syros Pharmaceuticals (NASDAQ: SYRS):

• 11/21/2024 – Syros Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/13/2024 – Syros Pharmaceuticals had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock, down previously from $6.00.
• 11/13/2024 – Syros Pharmaceuticals had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 11/13/2024 – Syros Pharmaceuticals had its “hold” rating reaffirmed by analysts at Brookline Capital Management.
• 11/13/2024 – Syros Pharmaceuticals had its “hold” rating reaffirmed by analysts at TD Cowen.
• 11/4/2024 – Syros Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/1/2024 – Syros Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 10/15/2024 – Syros Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/7/2024 – Syros Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS opened at $0.27 on Friday. The business’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $3.64. Syros Pharmaceuticals, Inc. has a twelve month low of $0.18 and a twelve month high of $8.17. The stock has a market cap of $7.24 million, a P/E ratio of -0.09 and a beta of 1.59. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the firm posted ($1.35) earnings per share. As a group, equities analysts predict that Syros Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling at Syros Pharmaceuticals

In other news, CEO Conley Chee acquired 50,000 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the transaction, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Jason Haas acquired 45,344 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the completion of the transaction, the chief financial officer now directly owns 124,552 shares in the company, valued at approximately $209,247.36. The trade was a 57.25 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 130,707 shares of company stock valued at $206,491 in the last 90 days. Corporate insiders own 12.26% of the company’s stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Kennedy Capital Management LLC bought a new position in Syros Pharmaceuticals during the 1st quarter worth approximately $2,166,000. Vanguard Group Inc. grew its position in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares during the last quarter. Virtu Financial LLC bought a new position in Syros Pharmaceuticals during the 1st quarter worth approximately $64,000. Acadian Asset Management LLC bought a new position in Syros Pharmaceuticals during the 1st quarter worth approximately $91,000. Finally, Certuity LLC bought a new position in Syros Pharmaceuticals during the 2nd quarter worth approximately $109,000. 91.47% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.